• Erastin as a Precision Ferroptosis Inducer in Cancer Biology

  2026-05-30

  Erastin is a validated ferroptosis inducer that enables targeted, iron-dependent cell death in RAS/BRAF-mutant tumor cells. This guide details optimized protocols, advanced applications, and troubleshooting strategies to maximize experimental reliability and insight for cancer biology research.

• Dose- and Time-Dependent Neurotoxicity of Ibotenic Acid in M

  2026-05-29

  This study systematically characterizes the acute neurotoxic effects of ibotenic acid in mice, revealing a distinct dose- and time-dependent toxicity profile. The findings offer new in vivo insights into early neuronal injury markers, supporting the refinement of neurodegenerative disease models and informing clinical strategies for mushroom poisoning.

• O-GlcNAcylation in Wnt-Stimulated Bone Formation and Glycoly

  2026-05-29

  This paper identifies O-GlcNAcylation as a critical mediator in Wnt3a-induced bone formation, linking post-translational modification to metabolic rewiring in osteoblasts. The findings clarify the dual mechanisms of Wnt signaling in promoting aerobic glycolysis and osteogenesis, offering new directions for targeted bone anabolic therapies.

• Folate-Targeted Nanoactivators Induce Ferroptosis in Pancrea

  2026-05-28

  Gupta et al. 2025 introduce radiocleavable, folate-functionalized rare-earth nanoparticles as a targeted approach to trigger ferroptosis and immunogenic cell death in pancreatic cancer. This strategy remodels the tumor microenvironment and suggests a route to overcoming chemoresistance in dense, poorly vascularized tumors.

• IBDV VP3-Driven IRF7 Degradation: Ubiquitin-Proteasome Mecha

  2026-05-28

  This study reveals that infectious bursal disease virus (IBDV) exploits its VP3 protein to promote the proteasomal degradation of interferon regulatory factor 7 (IRF7), suppressing the host's type I interferon response and facilitating viral replication. These findings illuminate a novel immune evasion strategy and underscore the centrality of ubiquitin-proteasome system modulation in host-pathogen interactions.

• Annexin V-FITC/PI Apoptosis Assay Kit: Precision in Hepatic

  2026-05-27

  Explore how the Annexin V-FITC/PI Apoptosis Assay Kit enables high-resolution apoptosis detection in liver injury and transplantation research. Learn why this APExBIO solution is uniquely suited for mechanistic studies of hepatocyte apoptosis, with insights bridging peptidomics and translational assay design.

• Lactobacillus gasseri Enhances Intestinal Barrier via NR1I3–

  2026-05-27

  Qian et al. (2024) demonstrate that Lactobacillus gasseri ATCC33323 alleviates DSS-induced colitis in mice by regulating intestinal E-cadherin expression through NR1I3. This mechanistic insight advances understanding of probiotic interventions for IBD and highlights E-cadherin as a critical mediator in maintaining mucosal barrier integrity.

• Otilonium Bromide: Antimuscarinic Agent for Cholinergic Path

  2026-05-26

  Otilonium Bromide is a high-purity antimuscarinic agent used to modulate cholinergic signaling pathways in neuroscience and smooth muscle research. Its robust solubility and selectivity enable reproducible inhibition of acetylcholine receptors, facilitating precise experimental workflows. APExBIO supplies Otilonium Bromide (SKU: B1607) as both a powder and 10 mM solution, supporting diverse in vitro applications.

• Afatinib (BIBW 2992) in Patient-Derived Assembloid Research

  2026-05-26

  Afatinib’s irreversible inhibition of EGFR, HER2, and HER4 uniquely empowers physiologically relevant assembloid models for cancer biology research. This guide demystifies practical workflows and troubleshooting strategies, integrating the latest breakthroughs in patient-derived tumor modeling.

• 3-(1-methylpyrrolidin-2-yl)pyridine (N2703): Precision Tools

  2026-05-25

  Explore how 3-(1-methylpyrrolidin-2-yl)pyridine (N2703) advances the study of adipose-neural interactions and cardiac arrhythmia. This article uncovers new experimental frameworks and protocol insights that set it apart from prior reviews.

• ATRX Loss Sensitizes High-Grade Glioma to RTK and PDGFR Inhi

  2026-05-25

  The reference study identifies that high-grade glioma cells deficient in the chromatin remodeler ATRX are significantly more sensitive to multi-targeted receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors. This finding highlights the need to factor ATRX mutation status into experimental design and clinical trial interpretation for targeted therapies in gliomas.

• Strategic Apoptosis Quantification: Translating Mechanism to

  2026-05-24

  This thought-leadership article delivers a rigorous exploration of how precise apoptosis quantification—anchored by the Annexin V-FITC/PI Apoptosis Assay Kit—empowers translational researchers to bridge mechanistic insight with actionable therapeutic strategies. Drawing on the latest advances in phosphatidylserine externalization detection, flow cytometry, and infection-driven wound healing, the discussion integrates new evidence from nano-therapeutic research against Pseudomonas aeruginosa and situates the APExBIO platform at the nexus of apoptosis research and clinical innovation. Detailed protocol guidance, competitive benchmarking, and an evidence-based outlook are provided.

• Cimetidine Applications: Advanced Workflows in Cancer and BB

  2026-05-23

  Cimetidine stands out as a versatile histamine-2 receptor antagonist, uniquely positioned for both cancer research and blood-brain barrier (BBB) permeability assays. Explore how its robust solubility, partial agonist activity, and validated purity empower high-throughput and reproducible experimental workflows.

• Maraviroc (UK-427857): Mechanistic Insights and Translationa

  2026-05-22

  Discover how Maraviroc, a selective CCR5 antagonist, advances both HIV-1 entry inhibition and neuroinflammation modulation. This article uniquely explores mechanistic details and translational strategies for Maraviroc in experimental and clinical research.

• Praeruptorin A Suppresses Poly (I:C)-Induced Inflammatory Pa

  2026-05-22

  The reference study demonstrates Praeruptorin A's ability to inhibit NF-κB activation and key inflammatory gene expression in poly (I:C)-stimulated RAW264.7 macrophages. These findings provide mechanistic insight into NF-κB-targeted anti-inflammatory strategies and inform the design of inflammation assay models relevant for viral and immune response research.

12943 records 1/863 page Next 12345 下5页 Last page